Symdeko to treat the underlying cause of cystic fibrosis in people ages 12 and older with certain mutations in the CFTR gene: FDA approved
The U.S. Food and Drug Administration ( FDA ) has approved Symdeko ( Tezacaftor / Ivacaftor and Ivacaftor ) for treating the underlying cause of cystic fibrosis in people ages 12 and older who have tw ...
read article